Serial biotech entrepreneur joins leading small molecule tau modulation company Lausanne, SWITZERLAND and Cambridge, MA, USA, January 17, 2019 – Asceneuron, an emerging leader in the development of orally bioavailable … Continue reading “Asceneuron appoints Peter Van Vlasselaer as Chairman”
Calliditas Therapeutics AB (publ) (NASDAQ Stockholm: CALTX) (“Calliditas”) today announced the appointment of Andrew Udell as Vice President, North America Commercial, effective February 1, 2019. Mr. Udell will be part … Continue reading “Calliditas Therapeutics AB appoints Andrew Udell to VP Commercial, North”
● New investor Morningside Venture joins existing blue-chip investor syndicate ● Company accelerates global phase 2b study of lead candidate olorofim to develop its novel antifungal in an area of … Continue reading “F2G expands investor syndicate and progresses Phase IIb study for novel antifungal”
2018 was a very successful year for our team and our portfolio companies, with six new investments, two portfolio companies closed major financing rounds, the launch of the REPAIR Impact … Continue reading “Novo Seeds Announces Record Year for Investment and Company Creation”
Significant Progress in Lead Programmes Cambridge, UK, 20th December 2018: Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, … Continue reading “Nuformix plc: Unaudited Half Year Results – Significant progress in lead programmes”
Turku, Finland – 18 December 2018: DelSiTech Ltd, a Finnish drug delivery technology and drug development company and Innovare R&D, a leading Mexican pharmaceutical company, have signed a world-wide, exclusive … Continue reading “DelSiTech and Innovare Sign Licensing Agreement for the Development of a Long Acting HIV Therapy”
17 December 2018 Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces plans to host … Continue reading “Futura Medical to Host R&D Day in February 2019”
Experienced industry executive joins investment team to support portfolio development LONDON, 11 December 2018: Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, today … Continue reading “Arix appoints Dr Christian Schetter as Entrepreneur In Residence (EIR)”
Appoints CNS specialist and establishes US presence with new office in Cambridge, MA Lausanne, SWITZERLAND and Cambridge, MA, USA, December 6, 2018 – Asceneuron, an emerging leader in the development … Continue reading “Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer”
LONDON, 3 December 2018: Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation notes its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL) (“Autolus”), announced … Continue reading “Autolus announces update on AUTO4 and AUTO5 programmes”
Data show Nuformix Investigational Candidates (NXP002) outperform current standard of care Cambridge, UK, 3rd December 2018: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of … Continue reading “Nuformix Reports Results from Novel Pre-Clinical Trial in IPF for NXP002 Programme”
Receives First Milestone Payment for NXP001 Cambridge, UK, 27 November 2018: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces … Continue reading “Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care product”
Venture fund focuses on supporting early stage healthcare and tech companies 27 November 2018, Amsterdam: INKEF Capital (INKEF), the Dutch venture capital fund focused on technology and healthcare, announces the … Continue reading “INKEF Capital Appoints Roel Bulthuis as Managing Director to Co-Manage Eur 500m Fund”
Major milestone in development of novel treatment for progressive supranuclear palsy and other tau-related dementias Asceneuron SA, an emerging leader in the development of innovative small molecules for the treatment … Continue reading “Asceneuron initiates neuroimaging trial for tau modifier ASN120290”
Amsterdam, The Netherlands, November 8, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it has appointed … Continue reading “Kiadis Pharma strengthens core team with three senior appointments”
Seasoned CEO with 30 years’ experience in the healthcare industry Edinburgh, United Kingdom – 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular imaging company, today announces the appointment … Continue reading “Edinburgh Molecular Imaging Appoints Bernhard Sixt as new Chief Executive Officer”
Amsterdam, The Netherlands, November 7, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces two data presentations at … Continue reading “Kiadis Pharma announces abstracts and presentations for the 60th American Society of Hematology (ASH) Annual Meeting”
Phase 1 data show favourable safety profile Data support further development of AP30663 for cardioversion therapy COPENHAGEN, Denmark — 5 November 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech … Continue reading “Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation”
Embark was first incubated by Novo Seeds and funded through the pre-seed grant programme of the Novo Nordisk Foundation in 2016 Embark co-founder and CEO, Casper Tind Hansen, serves as … Continue reading “Novo Seeds incubatee Embark Biotech enters collaboration with Novo Nordisk to discover novel therapeutics for obesity and metabolic disease”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2019 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com